All News
Filter News
Found 88 articles
-
Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
9/6/2023
Elicio Therapeutics, Inc. today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023 at 9:30 a.m. ET.
-
Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer
9/5/2023
Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that additional data from the Phase 1 (AMPLIFY-201) study of its lead asset, ELI-002, will be presented in a poster presentation at the upcoming AACR Special Conference on Pancreatic Cancer taking place in Boston, Massachusetts from September 27-30, 2023.
-
Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics
8/28/2023
Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics.
-
Elicio Therapeutics Reports Inducement Grants - August 22, 2023
8/22/2023
Elicio Therapeutics announced that on August 21, 2023, the Company’s board of directors approved the grant of 72,980 inducement stock options to two new employees, as an inducement material to each employee entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635.
-
Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
8/11/2023
Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2023 and provided recent corporate and clinical updates.
-
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating AMP-CpG Adjuvant Can Induce Potent and Durable Immune Response in Epstein-Barr Virus (EBV) Infectious Disease Model
8/9/2023
Elicio Therapeutics today announced the publication of preclinical data demonstrating its lymph node-targeting Amphiphile (AMP) adjuvant.
-
GI Research Foundation Quickly Delivers Nearly $18.5 Million to Study Gastrointestinal Cancers
6/27/2023
The GI Research Foundation announced that its CA CURE campaign drove the largest grantmaking year in its 60-year history.
-
Elicio Therapeutics Completes Reverse Merger and Provides a Corporate Update
6/6/2023
Elicio Therapeutics (NASDAQ:ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, provides a corporate update on a series of advancements for the company, including the completion of its reverse merger earlier this month in an all-stock transaction.
-
Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting
6/3/2023
Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, announced positive interim clinical data from the ongoing Phase 1 study of its lead asset, ELI-002, an investigational therapeutic cancer immunotherapy.
-
Elicio Therapeutics Reports Inducement Grant to New Chief Financial Officer
6/2/2023
Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the grant of an inducement award to the Company’s newly appointed Chief Financial Officer, Brian Piekos.
-
Elicio Therapeutics Announces Completion of Merger with Angion Biomedica
6/1/2023
Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the closing of its previously announced merger with Angion Biomedica Corp.
-
Elicio Therapeutics to Present Interim Data from the Ongoing Phase 1 Study of Investigational Therapeutic Cancer Vaccine, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at ASCO
5/1/2023
Elicio Therapeutics announced that interim data from the Phase 1 study of its lead asset, ELI-002, will be presented in a poster discussion presentation at the upcoming 2023 American Society of Clinical Oncology Annual Meeting, a hybrid event taking place online and at McCormick Place in Chicago from June 2-6, 2023.
-
Elicio Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Lymph Node-Targeted Investigational Therapeutic Vaccine ELI-002 7P (AMPLIFY-7P) in KRAS/NRAS Mutated Solid Tumors
4/27/2023
Elicio Therapeutics today announced the first patient has been dosed in the Phase 1/2 study of ELI-002 7P (AMPLIFY-7P) in KRAS/NRAS mutated solid tumors at Northwell Health Cancer Institute and the Feinstein Institutes for Medical Research, New York.
-
KRAS Inhibitor Drug LUMAKRAS Sotorasib Krazati Adagrasib Market Forecast 2029
2/3/2023
Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029 Report Highlights:
-
Elicio Therapeutics entered into a merger agreement as a wholly-owned subsidiary of Angion Biomedica Co. on Tuesday, becoming a Nasdaq-listed company.
-
Elicio Therapeutics and Angion Enter into Definitive Merger Agreement
1/17/2023
Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction.
-
The GastroIntestinal Research Foundation Launches New Multi-Million Dollar Funding Initiative Aimed at Curing Cancers of the Digestive System
11/9/2022
Despite centuries of research, treating and curing cancer remains an urgent health research priority. With generous support from anonymous donors, the GastroIntestinal Research Foundation (GIRF) has launched a bold initiative, CA CURE, to identify and fund research to improve diagnostics and develop therapeutics focused on immunotherapies and personalized vaccines.
-
Elicio Therapeutics Announces Publication of Preclinical Data in Science Translational Medicine Demonstrating the AMP Platform Promotes Uptake of Intranasal Vaccine in the Mucosa Amplifying Immune Response
10/4/2022
Elicio Therapeutics announced the publication of preclinical data from the research laboratory of Dr. Darrell Irvine at the Massachusetts Institute of Technology, demonstrating Elicio’s Amphiphile platform conjugated to protein antigens promotes uptake in the nasal mucosa and amplifies immune responses after intranasal immunization.
-
Advances in immuno-oncology and adaptive cell therapy that began about a decade ago are enabling fresh, biology-driven approaches to bring therapeutic cancer vaccines closer to fruition.
-
Elicio Therapeutics Receives $2.8 Million Grant from the Gastro-Intestinal Research Foundation (GIRF) to Fund Research for Two Therapeutic Cancer Vaccines
9/20/2022
Elicio Therapeutics announced that it has been awarded a $2.8 million grant from the Gastro-Intestinal Research Foundation in Chicago to fund research for two therapeutic cancer vaccines.